Why the study?
Does the use of COX-2 inhibitors increase the risk of incident cardiovascular events in a population without prior cardiovascular disease?
Population
6,991,645 subjects without prior cardiovascular diagnosis from a nation-wide, population-based cohort
Comparison
Selective cyclooxygenase-2 inhibitors use… vs Non-use of COX-2 inhibitors
Design
Cohort
Follow-up
from 1 July 2005 to 31 December 2008
Authors
Loading...
May support AF vigilance with coxibs in primary prevention; leaves open causality and effects on other CV events.
Does the use of COX-2 inhibitors increase the risk of incident cardiovascular events in a population without prior cardiovascular disease?
Use of COX-2 inhibitors, particularly etoricoxib, is associated with an increased risk of incident atrial fibrillation in patients without prior cardiovascular disease.
Bäck et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: